BAIBYS’ system examines sperm samples and automatically selects ideal sperm according to WHO criteria, both in terms of their motility and morphology.

Israeli startup BAIBYS, which has developed an autonomous system for selecting ideal sperm for fertility treatments, aiming to improve treatment success rates and reduce birth defects, has announced the completion of its $4.5 million Series A funding round, led by Firstime Ventures, with participation from Japanese pharmaceutical giant ROHTO.

BAIBYS was founded in 2020 by Dr. Nino Guy Cassuto, a Jewish-French doctor specializing in male fertility, and Gal Golov, an engineer expert in electro-optics who personally experienced the multifaceted difficulties inherent in repeated failed fertility treatments.

Gal Golov and Dr. Yaron Silberman serve as co-CEOs of the company, which currently employs eight full-time workers at its offices in Ramat Hahayal, Tel Aviv, as well as several part-time employees and expert consultants in their respective fields.